Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675901 | 0.91 | MAPK1 (0.39) | CDK2CCNE1MAPK1 | |
| SCHEMBL18556902 | 0.87 | CCNE1 (0.39) | CDK2CCNE1MAPK1RET | |
| SCHEMBL16675925 | 0.87 | CDK2 (0.39) | CDK2CCNE1MAPK1LCKRET | |
| SCHEMBL16675920 | 0.85 | CDK2 (0.39) | CDK2CCNE1MAPK1LCKRET | |
| SCHEMBL16675903 | 0.83 | MAPK1 (0.39) | CDK2CCNE1MAPK1CTSKCCNA2 | |
| SCHEMBL16675893 | 0.81 | MAPK1 (0.38) | CDK2CCNE1MAPK1LCKRET | |
| SCHEMBL16675908 | 0.81 | MAPK1 (0.39) | CDK2CCNE1MAPK1RETCTSK | |
| SCHEMBL16675923 | 0.80 | RET (0.38) | CDK2LCKRETSRCCCNA2 | |
| SCHEMBL16675916 | 0.79 | CDK2 (0.48) | CDK2CCNE1MAPK1RETCCNA2 | |
| SCHEMBL18556886 | 0.79 | CCNE1 (0.38) | CDK2CCNE1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CDK2 3048/4885CCNE1 3962/4885MAPK1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.